XP Chemistries
XP Chemistries is a Swedish biotechnology company focused on developing and commercializing high-purity capsaicin and capsaicin-based formulations. The business is organized around ingredient supply and application development for animal feed, supplements, and adjacent life science uses, with operations based in Sundsvall, Sweden.
Fiscal year 2025 · change from previous year
Development 2021–2025
Business
Share of revenueCapsaicin products and formulations intended for use as fodertillsats in animal nutrition.
Capsaicin ingredients marketed through distributors and partners for supplement applications.
Partnered development and ingredient use cases in more advanced life science settings.
Technical work to adapt capsaicin formats, specifications, and delivery properties for customers.
Customers
XP Chemistries sells primarily to B2B customers rather than end consumers. Its buyers include feed ingredient distributors, commercial partners, supplement companies, and development partners that need standardized capsaicin inputs and technical documentation. The company also targets more specialized life science and pharmaceutical counterparties for longer-term application development.
Buy capsaicin-based feed additives and formulations for resale into EU and selected export markets.
Use capsaicin as an ingredient in animal nutrition products to support feed formulations.
Purchase capsaicin ingredients for standardized supplement and special nutrition products.
Evaluate capsaicin for more advanced applications and longer-term development programs.
Work with XP Chemistries on testing, formulation, and market access rather than direct consumer sales.
Strategy
The company’s strategy is to commercialize high-purity capsaicin through partners and distributors rather than building a broad direct-sales organization. It aims to win adoption by combining regulatory approval, standardized product formats, and technical formulation work that improves usability and customer value. Over time, XP Chemistries seeks to expand from feed applications into supplements and other life science uses where capsaicin can be sold as a specialized ingredient.
EU approval unlocks the company’s main near-term market and allows sales through feed channels.
Partners provide market access and scale without requiring a large internal sales organization.
The company believes value is created by the right formulation, not only the molecule itself.
These adjacent markets can broaden the addressable market for capsaicin ingredients.
Geography
XP Chemistries is headquartered in Sundsvall, Sweden, and its commercial focus is centered on Europe, especially the EU animal feed market. The company also references selected markets outside the EU through distribution partnerships, and its patent footprint spans multiple countries across North America, Europe, and Asia. Geography matters because regulatory approval in the EU is central to commercialization, while partner-led distribution can extend reach without a large local sales force.
Risks
XP Chemistries depends on regulatory acceptance, customer adoption, and successful scale-up of a specialized ingredient business. The company also faces typical biotech and ingredient-market risks such as product development uncertainty, manufacturing execution, and reliance on partners for commercialization. Because the business is early-stage and concentrated in capsaicin applications, delays in market uptake or technical validation could materially affect growth.
- Customer adoption and market educationImpact: HighLikelihood: Medium
Buyers must validate product performance, handling, and economics before switching to a new ingredient.
Exposure: Feed distributors and supplement customers
- Regulatory dependence for EU feed commercializationImpact: HighLikelihood: Low
The main market opportunity relies on formal approval and continued compliance in the EU.
Exposure: Animal feed capsaicin sales
- Manufacturing and scale-up executionImpact: MediumLikelihood: Medium
The company needs reliable contract manufacturing and consistent product quality to supply commercial volumes.
Exposure: High-purity capsaicin and formulations
- Partner concentrationImpact: Medium
A partner-led model can create dependence on a small number of distributors or commercial counterparties.
Exposure: EU and selected export markets
Accounting
Judgemental itemsWith low absolute revenue, timing of small orders or pilot deliveries can materially affect quarterly results.
Impact: Reported turnover may be volatile and not fully indicative of run-rate demand
The value of patents, product development, and subsidiary investments depends on future commercialization success.
Impact: Write-downs could affect equity and operating results
The business has relied on share issues and warrants to fund operations.
Impact: Dilution and equity movements can be significant
The company uses consultants connected to the broader Organofuel/XP Chemistries group.
Impact: Important for expense classification and governance review
Similar listed companies
Publicly listed companies with a comparable business focus.
Axfood
AXFO · Consumer Staples
Axfood is a prominent player in the Swedish food retail market, operating a diverse range of grocery store concepts including Willys, Hemköp, and City Gross.
Oncopeptides
ONCO · Health Care
Oncopeptides is a Swedish biopharmaceutical company focused on developing and commercializing therapies for difficult-to-treat hematological diseases.
Exelixis, Inc
EXEL · Biological Products, (No Diagnostic Substances)
Exelixis is a U.S.-based oncology company built around cabozantinib, which it markets as CABOMETYX and COMETRIQ and uses as the core of its commercial revenue base.
XP Inc.
XP · Security Brokers, Dealers & Flotation Companies
XBiotech Inc.
XBIT · Pharmaceutical Preparations
MBX Biosciences, Inc.
MBX · Pharmaceutical Preparations
Last updated: 24/09/2026